We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Our team comes to work every day with a sustained commitment to improving human health - and it's what pushes us to innovate. At Deciphera, we are united in our goal to defeat cancer by addressing key mechanisms of tumor and drug resistance that limit the results of some existing therapies.
We leverage our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. Since becoming a member of ONO Group in June 2024, we have continued expanding our global footprint while maintaining our dedication to patients. We design switch-control kinase inhibitors with the goal of potentially improving patient responses to treatment and, ultimately, patient outcomes.